Thymic immunomodulatory peptide (thymalfasin / Zadaxin)
A thymus-derived 28-amino-acid peptide that regulates and strengthens immune responses; sold as prescription drug Zadaxin abroad.
| Class / type | Thymic immunomodulatory peptide (thymalfasin / Zadaxin) |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide from the thymus, the gland that trains immune cells. As the drug thymalfasin (Zadaxin), it's approved in more than 35 countries - though not by the US FDA - for hepatitis and as an immune adjunct.
It has an unusually deep clinical record for a 'peptide,' which sets it apart from most research-use compounds.
It acts on dendritic cells through toll-like receptors (TLR2/TLR9), strengthening Th1 pathogen defense while also promoting immune tolerance. In practice it behaves as an immune normalizer - boosting weak responses and helping rein in dysregulated ones.
It's been studied across 30+ trials and thousands of subjects for chronic hepatitis B and C, as a chemotherapy adjunct, for immune restoration, and (more recently) sepsis and COVID-19, with a consistently favorable safety profile at therapeutic doses.
A long clinical track record and strong safety data relative to newer peptides; users and patients cite immune resilience, fewer infections and better recovery.
Approved and used medically in many countries.
Not FDA-approved in the US; benefit varies by indication. As an immunomodulator, caution is warranted in autoimmune conditions.
Injection-site reactions are possible, and US compounded supply raises purity questions.
Approved abroad as Zadaxin/thymalfasin; in the US it's compounded. It was among peptides reportedly moved toward compounding access in 2026, but confirm current status.
Immune resilience / fewer infections and recovery support; valued for its long clinical track record.
NOT FDA-approved in the US (approved abroad as Zadaxin in dozens of countries). An FDA advisory committee voted 17-4 against adding it to the 503A compounding list in December 2024, and it was not part of the July 2026 review, so it cannot lawfully be compounded by 503A pharmacies.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.